Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2010 by Telik.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
Telik
Information provided by (Responsible Party):
Telik
ClinicalTrials.gov Identifier:
NCT01062152
First received: February 2, 2010
Last updated: October 17, 2012
Last verified: February 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is ongoing, but not recruiting participants. |
|---|---|
| Estimated Study Completion Date: | November 2012 |
| Estimated Primary Completion Date: | November 2012 (Final data collection date for primary outcome measure) |
No publications provided by Telik
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):